Unknown

Dataset Information

0

Survival Analysis of Pathological T3a Upstaging in Clinical T1 Renal Cell Carcinoma.

ABSTRACT: AIM:To evaluate the oncological outcomes of pathological T3a upstaging from clinical T1 renal cell carcinoma. PATIENTS AND METHODS:We retrospectively studied patients who underwent radical or partial nephrectomy for clinical T1 renal tumors. RESULTS:The median follow-up period was 44 months. At three and five years, the respective overall survival rate was 88.7% and 82.4% in pT3a disease, 95.7% and 93.4% in pT1 (p=0.008), the cancer-specific survival rate, 93.9% and 90.8% in pT3a, 99% and 97.7% in pT1 (p=0.001), and the recurrence-free survival rate, 79.7% and 71.0% in pT3a, and 95.5 and 94.3% in pT1 (p<0.001). CONCLUSION:Patients with pathological T3a upstaging tumors were associated with a significantly decreased survival rate, along with a higher recurrence rate when compared to those with pathological T1 disease.

SUBMITTER: Lai GS 

PROVIDER: S-EPMC7157890 | biostudies-literature | 2020 Mar-Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Survival Analysis of Pathological T3a Upstaging in Clinical T1 Renal Cell Carcinoma.

Lai Gu-Shun GS   Li Jian-Ri JR   Wang Shian-Shiang SS   Chen Chuan-Shu CS   Yang Chun-Kuang CK   Hung Sheng-Chun SC   Cheng Chen-Li CL   Ou Yen-Chuan YC   Chiu Kun-Yuan KY  

In vivo (Athens, Greece) 20200301 2

<h4>Aim</h4>To evaluate the oncological outcomes of pathological T3a upstaging from clinical T1 renal cell carcinoma.<h4>Patients and methods</h4>We retrospectively studied patients who underwent radical or partial nephrectomy for clinical T1 renal tumors.<h4>Results</h4>The median follow-up period was 44 months. At three and five years, the respective overall survival rate was 88.7% and 82.4% in pT3a disease, 95.7% and 93.4% in pT1 (p=0.008), the cancer-specific survival rate, 93.9% and 90.8% i  ...[more]